Tuesday, 28 July 2026
Peptide prescribing guidance update, Global taskforce on skin bleaching, Ventolin shortage until late 2028
- 01
New guidance on peptide prescribing being developed in Australia
The Medical Board of Australia is developing new guidance for prescribing off-label, unapproved, and compounded medicines in response to the rising use of unapproved peptides. This initiative aims to clarify professional responsibilities for practitioners amid concerns that high consumer demand may lead to unsafe prescribing practices. The guidance will remind prescribers to assess patient suitability, obtain informed consent, and document consultations. The Therapeutic Goods Administration is also increasing compliance actions against unapproved peptide products, highlighting the regulatory focus on patient safety.
- 02
Global initiative addresses skin bleaching public health crisis
The International League of Dermatological Societies (ILDS) has launched a global taskforce to combat the health risks associated with skin bleaching, which is an under-recognised public health issue in Australia. The initiative aims to educate consumers and healthcare professionals about the dangers of unregulated skin lightening products, many of which contain harmful ingredients. Sydney dermatologist Professor Stephen Shumack highlighted that while the issue is more prevalent in other countries, Australia is not immune, particularly among culturally diverse communities. The taskforce will focus on promoting safer skin health practices and addressing the psychological impacts of skin bleaching.
- 03
Ventolin shortage projected to last until late 2028
Australia faces a significant shortage of Ventolin, expected to continue until late 2028. This situation raises concerns for asthma management across the country. An expert suggests that the shortage presents an opportunity to remind patients and healthcare professionals about alternative treatments and national guidelines. The ongoing shortage may impact the availability of this essential medication for asthma patients.
- 04
Antibiotic resistance projected to rise in children, remote communities
Resistance to last-line antibiotics is projected to reach 82% within the next decade, particularly affecting children and remote communities in Australia. A study published in JAMA Pediatrics indicates that antimicrobial resistance (AMR) is increasing globally among children, with remote areas facing rates up to four times higher than the national average. The Murdoch Children’s Research Institute has launched a monitoring platform to analyse resistance patterns, while Flinders University has received funding for a project aimed at addressing AMR in the Northern Territory. The TARRA project will develop a remote antimicrobial stewardship program tailored for local primary healthcare settings.
- 05
Optimal RSV Immunisation Timing Linked to Birth Season
New research from Western Australia suggests that the timing of RSV immunisation for infants should depend on their birth season to reduce hospitalisations. The study indicates that summer-born infants are at peak risk for RSV-related hospitalisations between five and eight months, while spring-born infants peak between eight and ten months. By administering nirsevimab prior to the RSV season, the researchers estimate that an additional 65 hospitalisations could be averted annually. The findings are based on data from over 411,900 births and highlight the need for tailored immunisation strategies.
- 06
Strategies for Managing Menopause-Related Skin Issues
A recent article discusses practical strategies for managing skin issues associated with menopause, including dry skin, midlife acne, genitourinary symptoms, and hair loss. The content is specifically aimed at AHPRA registered professionals. This information may assist clinicians in addressing these common concerns in their patients during midlife.
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.